The FDA granted full approval encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil-based ...
Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results